Abhivandan Nagia’s Post

🆕📝 In June 2024, the FDA - La Administración de Alimentos y Medicamentos published the final version of the Oligonucleotide Therapeutics Guidance, which replaced the draft from 2022. This document provides recommendations for the industry in developing these therapies but poses new challenges for developers and manufacturers. In our latest post, our team revised this final version and prepared a summary of the most critical aspects and how Kymos Group can assist you in dealing with them. ▶ Learn more about the new guide and Kymos' capabilities: https://lnkd.in/dNQv4_fd

📢 Exciting News from DelveInsight Business Research LLP! 🌟 Explore the latest advancements in the Spinal Muscular Atrophy (SMA) Pipeline with our comprehensive report! 🧬 The report provides in-depth insights into emerging therapies, key companies, and ongoing clinical trials that are shaping the future of #SMAtreatment. The leading #SpinalMuscularAtrophyCompanies such as Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics Inc. ANDROSCIENCE CORPORATION, Hanugen Therapeutics, Voyager Therapeutics, Inc., Roche, Catalyst Pharmaceuticals, Inc., NMD Pharma A/S, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc. Aurimed Pharma, Exicure, Amylon Therapeutics Amniotics AB, and others. Stay ahead in the evolving #SMAlandscape! 🔬 Get More Insights @ https://lnkd.in/dJH9G75r #SpinalMuscularAtrophy #SMA #PharmaPipeline #Biotech #HealthcareResearch #DelveInsight #ClinicalTrials #SMAAwareness #PharmaUpdates

Don’t miss the scientific insights of our own William Boomershine, Ph.D. in his exclusive article in The Medicine Maker, Navigating the Analytical Complexity of Oligonucleotide Therapeutics. In it, he shares how to overcome the analytical complexities inherent to oligonucleotide manufacturing, which can unlock untold health benefits of valuable new patient therapies and vaccines. Read the full article ➡️ https://hubs.li/Q02Rvgcb0 #Alcami #TheMedicineMaker #Oligonucleotides #biopharma #pharma #AskAlcami

Interested in the advancements in complement therapeutics? Don't miss our latest case study showcasing an alternative use of our Properdin assay. Learn about functional assessment of Properdin and the AP- C3 convertase and its impact on drug development. https://hubs.ly/Q02DSnHZ0 #ComplementingLifeScience #AnswersinLifeScience #Complementsystem #Complementbiology #AlternativePathway #Properdin #drugdevelopment

🚨A reminder to register for the upcoming webinar on how to accelerate the development and production of AAV-based therapeutics!  Learn from Regeneron’s Marília Barros and Refeyn’s Matthew Ranaghan about the best analytical strategies to analyze the ratios of empty/full/partial AAV ratios, capsid titers, sample purity and other key quality attributes essential for successful drug development. And of course, how to integrate #MassPhotometry in your workflows for fast, sample-efficient analysis. 🔬📊  Register here 👉 https://lnkd.in/dfMqa7dY

𝐃𝐲𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐚𝐭𝐚 𝐟𝐫𝐨𝐦 𝐏𝐡𝐚𝐬𝐞 𝟏/𝟐 𝐃𝐄𝐋𝐈𝐕𝐄𝐑 𝐓𝐫𝐢𝐚𝐥 𝐟𝐨𝐫 𝐃𝐘𝐍𝐄-𝟐𝟓𝟏 𝐢𝐧 𝐃𝐮𝐜𝐡𝐞𝐧𝐧𝐞 𝐌𝐮𝐬𝐜𝐮𝐥𝐚𝐫 𝐃𝐲𝐬𝐭𝐫𝐨𝐩𝐡𝐲 (𝐃𝐌𝐃) Dyne Therapeutics (Nasdaq: DYN) Dyne Therapeutics announced new data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in DMD patients amenable to exon 51 skipping, showing unprecedented dystrophin expression and functional improvement in multiple cohorts. The data highlight DYNE-251's potential to transform the treatment paradigm for Duchenne. Key findings include a mean dystrophin expression of 3.71% at 20 mg/kg, significant functional improvements, and a favorable safety profile. Dyne is now initiating registrational cohorts in the DELIVER trial and will provide an update on the path to registration by year-end 2024. #DMD #MuscularDystrophy #ClinicalTrials #Biotech #Pharma #RareDiseases #GeneTherapy #Biopharma #DrugDevelopment

Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced a major expansion of their partnership. Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs. The first involves broadening the therapeutic evaluation of an already partnered asset to reach more patients and the other a new asset acquisition: Reflecting an amendment of the existing col... https://buff.ly/3WS3wQZ Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced a major expansion of their partnership. Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs. The first involves broadening the therapeutic evaluation of an already partnered asset to reach more patients and the other a new asset acquisition: Reflecting an amendment of the existing col... #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

Thoughts on this? >> SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #productmarketing #pharma #healthcare

SFBN Feed: Novotech Publishes Report on the Global COVID-19 Clinical Trial Landscape, Highlighting Key Trends, Therapeutic Advancements, and Challenges in Drug Development https://lnkd.in/gMhjkZNE SAN FRANCISCO–(BUSINESS WIRE)– #COVID–Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics, has released an in-depth report “COVID-19: Global Clinical Trial [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: November 21 - 24, 2024 BridgeBio's Attruby lands FDA approval, Roche's Vabysmo touts potentially lucrative (in Asia) Ph3b/4 data in polypoidal choroidal vasculopathy, Nabla Bio's coming for the AI-designed protein crown, ALS hopeful Seelos Therapeutics files for bankruptcy + 21 more stories Get the full TLDR Biotech newsletter here: https://lnkd.in/gmQAMVfc